Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents